This inventor holds 7 USPTO granted patents. Top assignee: Hoffmann-La Roche Inc.. Active years: 1993-2012.
Company Filing History:
Years Active: 1993-2012
Title: Reiner Gentz: Innovator in TNF Receptor Research
Introduction
Reiner Gentz is a prominent inventor based in Rheinfelden, Germany. He has made significant contributions to the field of biochemistry, particularly in the development of proteins that interact with tumor necrosis factor (TNF). With a total of 7 patents to his name, Gentz has established himself as a key figure in medical research.
Latest Patents
Gentz's latest patents include groundbreaking work on the Human TNF receptor. This invention focuses on non-soluble proteins and their fragments that bind TNF in homogeneous form. It also covers the physiologically compatible salts of these proteins, particularly those with a molecular weight of about 55 or 75 kD under non-reducing SDS-PAGE conditions. The patent outlines a process for isolating such proteins, developing antibodies against them, and identifying DNA sequences that code for these proteins and their fragments. Another significant patent is the Human TNF receptor fusion protein, which shares similar characteristics and applications as the previous invention.
Career Highlights
Reiner Gentz is associated with Hoffmann-La Roche Inc., a leading company in the pharmaceutical industry. His work has been instrumental in advancing the understanding of TNF and its implications in various diseases. Gentz's innovative approaches have paved the way for new therapeutic strategies.
Collaborations
Throughout his career, Gentz has collaborated with notable colleagues, including Ernst-Jurgen Schlaeger and Werner Lesslauer. These partnerships have enhanced the research and development of TNF-related therapies.
Conclusion
Reiner Gentz's contributions to the field of biochemistry, particularly in TNF receptor research, have been invaluable. His patents and collaborations continue to influence the development of new medical treatments.